Rituximab and Hyaluronidase
Rituxan Hycela is a subcutaneous formulation of rituximab combined with hyaluronidase, allowing administration under the skin rather than by intravenous infusion. It is used to treat certain blood cancers and autoimmune conditions in patients who have received prior therapy with rituximab.
A subcutaneous formulation of rituximab for treating certain lymphomas, leukemia, and rheumatoid arthritis, offering a faster administration option.
Key facts at a glance
- RxNorm
- 1927886
- Generic
- Rituxan Hycela
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treatment of adults with previously untreated and relapsed/refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, previously untreated and treated chronic lymphocytic leukemia, and moderate to severe rheumatoid arthritis when used with methotrexate in patients who have had inadequate response to one or more TNF antagonist therapies.
Contains rituximab, a monoclonal antibody that binds to the CD20 protein on B-cells, causing their destruction. The hyaluronidase component temporarily breaks down hyaluronic acid in the subcutaneous tissue, allowing for better absorption and dispersal of the medication when given as a subcutaneous injection.
Administered as a subcutaneous injection (typically over 5-15 minutes) rather than an IV infusion. Pre-medication with corticosteroids, antihistamines, and acetaminophen is recommended to reduce risk of reactions. Requires monitoring for infections, infusion-related reactions, and cardiac effects. Patients should be observed during and after injection. Not interchangeable with intravenous Rituxan formulations. This medication has a boxed warning for fatal infusion reactions, severe mucocutaneous reactions, hepatitis B reactivation, and progressive multifocal leukoencephalopathy.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 9, 2026. · Read our editorial policy